Choo, J., Wu, A. J., Maron, S. B., Joshi, S. S., Ilson, D. H., Janjigian, Y. Y., Shcherba, M., Li, J., Tang, L. H., Sihag, S., Park, B. J., Jones, D. R., Molena, D., Ku, G. Y. (2026). Survival outcomes for phase II study of durvalumab (D) and tremelimumab (T) plus PET-directed chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma (EA).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.397